Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 7/20 | 0.41 |
| ▸ | RAF1 | P04049 | 4/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | HIPK4 | Q8NE63 | 7/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
| ▸ | PLK4 | O00444 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
| ▸ | LYN | P07948 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | ROS1 | P08922 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | FRK | P42685 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243328 | 0.89 | BRAF (0.39) | BRAFMAPK14KDRRAF1EPHX2 | |
| SCHEMBL2247488 | 0.87 | BRAF (0.48) | BRAFMAPK14KDRRAF1EPHX2 | |
| SCHEMBL2243568 | 0.80 | RAF1 (0.55) | BRAFMAPK14KDRRAF1EPHX2 | |
| SCHEMBL2248112 | 0.79 | KDR (0.43) | BRAFMAPK14KDRRAF1EPHX2 | |
| SCHEMBL2240645 | 0.78 | BRAF (0.42) | BRAFMAPK14KDRRAF1EPHX2 | |
| SCHEMBL2241177 | 0.78 | MAPK14 (0.43) | BRAFMAPK14KDRRAF1EPHX2 | |
| SCHEMBL2246414 | 0.78 | CSF1R (0.42) | BRAFMAPK14KDRRAF1EPHX2 | |
| SCHEMBL177543 | 0.78 | KDR (0.60) | BRAFMAPK14KDRRAF1EPHX2 | |
| SCHEMBL2245532 | 0.77 | ABL1 (0.56) | BRAFMAPK14KDRRAF1EPHX2 | |
| SCHEMBL2249059 | 0.76 | KDR (0.44) | BRAFMAPK14KDRRAF1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | claimed |
| EP-2044053-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | UMPS, SLC14A1, CPS1 | BRAF 338/4885MAPK14 3645/4885KDR 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.